FDA Advisory Panel Unanimously Endorses First mRNA Seasonal Flu Vaccine

On Thursday, the FDA's top vaccine advisory committee voted unanimously to recommend the first-ever mRNA-based seasonal influenza vaccine. In a pair of 9-0 votes, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) endorsed Moderna's mRNA-1010—branded as mFlusiva—for adults aged 50 to 64, and separately for those 65 and older.[1][6]

The endorsement marks a critical milestone in a turbulent regulatory journey, positioning the shot for potential approval by early August. If cleared, it will introduce the same genetic technology that altered the trajectory of the COVID-19 pandemic to the annual fight against the flu, a virus that causes hundreds of thousands of hospitalizations in the U.S. each year.[1][2]

For decades, the standard method for producing flu vaccines has relied on incubating viruses in chicken eggs—a process that takes roughly six months. Because of this long lead time, global health officials must predict which flu strains will circulate half a year in advance. When the virus mutates and those projections miss the mark, vaccine efficacy can plummet from 60% to as low as 19%.[5][7]

Messenger RNA technology bypasses the egg-based incubation entirely. Instead of injecting a weakened virus, mRNA vaccines deliver microscopic genetic instructions that prompt the body's own cells to produce flu antigens. This direct encoding reduces the manufacturing timeline to just two or three months, allowing health agencies to select target strains much closer to the start of flu season, drastically reducing the risk of a mismatch.[1][7]

The clinical evidence supporting mFlusiva rests primarily on the Phase 3 P304 trial, which enrolled 43,808 adults across 11 countries. The results, published in the New England Journal of Medicine, demonstrated that the mRNA vaccine provided significantly better protection against flu-like illness than standard-dose shots.[4][6]

Specifically, the trial showed a relative vaccine efficacy of 26.6% higher than the licensed standard-dose comparator. This efficacy held consistent across multiple influenza lineages, including A/H1N1, A/H3N2, and B/Victoria, meeting the FDA's prespecified criteria for both non-inferiority and superiority.[4][6]

Beyond the raw efficacy numbers, independent research suggests the mRNA platform may fundamentally alter how the immune system remembers the virus. A study published this month in Nature Immunology by researchers at Washington University School of Medicine found that mRNA-1010 triggers an immune response against a wider array of flu strains than traditional shots.[5]

By analyzing blood samples, researchers discovered that the mRNA vaccine produced more flu-specific memory B cells. These cells help expand and diversify the antibody response, potentially offering stronger and longer-lasting protection even when the virus begins to mutate away from the exact vaccine strain.[5][7]

However, the enhanced immune response comes with a trade-off in tolerability. According to FDA briefing documents, solicited adverse reactions were generally mild-to-moderate and resolved within two days. Yet, Grade 3 systemic reactions—such as severe fatigue, headache, and muscle pain—occurred more frequently with Moderna's shot (5.5%) than with the standard-dose comparator (0.9%).[6]

During the VRBPAC meeting, panel members acknowledged this higher reactogenicity, comparing it to other highly effective but physically taxing vaccines like the Shingrix shingles shot. While the panel concluded that the protective benefits heavily outweighed these temporary side effects, they noted that patient education will be crucial to manage expectations regarding post-vaccination discomfort.[1][6]

The unanimous vote represents a dramatic reversal of fortune for Moderna. In February, the FDA shocked the biopharmaceutical industry by issuing a refusal-to-file letter, effectively rejecting the application before the review even began.[3][7]

The agency's initial objection centered on the clinical trial design. Regulators argued that Moderna should have tested its vaccine against a high-dose flu shot—the preferred standard of care for older adults—rather than a standard-dose comparator. Moderna countered that the FDA had previously agreed to the standard-dose benchmark during trial planning.[2][3]

Following public backlash and high-level meetings, the FDA reversed its decision weeks later and accepted the filing. The regulatory friction coincided with leadership changes within the FDA's vaccine division, resulting in what industry analysts described as a more traditional, less adversarial review posture heading into Thursday's committee meeting.[3][7]

Despite the positive vote, the FDA highlighted several evidence gaps that require ongoing monitoring. Because the Phase 3 trial only covered a single flu season, the long-term durability of the mRNA protection remains unproven. Furthermore, the agency noted a lack of robust data regarding the vaccine's performance in severely immunocompromised individuals and very frail older adults.[6][7]

To address the comparator dispute for the oldest patients, Moderna is seeking a bifurcated approval: a standard approval for adults aged 50 to 64, and an accelerated approval for those 65 and older. The accelerated pathway requires Moderna to conduct a Phase 4 post-marketing study to definitively prove the vaccine's effectiveness in the senior population.[3][6]

The FDA is expected to issue its final decision by August 5. While the agency is not bound by advisory committee votes, it rarely deviates from unanimous recommendations. If approved, mFlusiva will not only disrupt the seasonal flu market but also lay the regulatory groundwork for Moderna's ultimate goal: a combined, single-shot vaccine protecting against both influenza and COVID-19.[2][3][7]